OSLO, 3 January 2023: 
EXACT Therapeutics AS ("EXACT-Tx" or the "Company") has today granted a total of
162,000 share options to employees of the Company, of which a total of 90,000
share options have been granted to primary insiders of the Company. Each option,
when exercised, gives the right to acquire one share in the Company. The shares
will be subject to a 12-month lock-up, subject to certain exemptions.
 
The share options expires one week after the date of the release of the
Company's half year results in 2027  and vest over a period of three years on
the date of the release of the half year results, whereby 25% vest in 2023, 25%
vest in 2024 and 50% vest in 2025. All options have an exercise price of NOK
12,69, which is subject to adjustment in the event of i) a change in the share
capital, ii)  a rights issue or repair issue, or iii) dividends or other
distributions in cash or in kind. The following primary insiders have been
granted share options:

-	Amir Snapir (Chief Medical Officer) has been granted 60,000 share options.
Following the grant, Snapir holds 60,000 share options in EXACT-Tx. 

-	John M. Edminson (Chief Financial Officer) has been granted 30,000 share
options. Following the grant, Edminson holds 30,000 share options in EXACT-Tx.

This information is subject to the disclosure requirements in Regulation EU
596/2014 (MAR) article 19 number 3 and section 5-12 of the Norwegian Securities
Trading Act.

For more information, please contact:

Per Walday, CEO, per.walday@exact-tx.com

About EXACT-Tx:
EXACT-Tx is a Norwegian clinical-stage precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101)
activated by ultrasound for enhanced drugtargeting deployed in multiple
indications to enhance the therapeutic efficacy of medicines through the use of
ultrasound-mediated drug delivery, for patients across multiple diseases.
www.exact-tx.com